Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, multi-centre, randomised, placebo-controlled, dose escalation study to assess local and systemic tolerability of therapeutic DNA plasmid pdpSC18 vaccine administered by Particle Mediated Epidermal Delivery using PowderJect ND10 delivery system in subjects with chronic hepatitis B infection

X
Trial Profile

Phase I, multi-centre, randomised, placebo-controlled, dose escalation study to assess local and systemic tolerability of therapeutic DNA plasmid pdpSC18 vaccine administered by Particle Mediated Epidermal Delivery using PowderJect ND10 delivery system in subjects with chronic hepatitis B infection

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hepatitis B DNA vaccine (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Nov 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
    • 20 Nov 2008 Actual trial completion date identified as December 2007 from ClinicalTrials.gov.
    • 04 Apr 2006 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top